Lipoprotein(a): Medical treatment options for an elusive molecule

Current Pharmaceutical Design

Volumn 17, Issue 9, 2011, Pages 871-876

  Parhofer, Klaus G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anacetrapib; Apoprotein(a); Ascorbic acid; Carnitine; Dalcetrapib; Eprotirome; Mipomersen; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANACETRAPIB; ANTIANDROGEN; ASCORBIC ACID; ATORVASTATIN; CARNITINE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EPROTIROME; ESTRADIOL; ESTROGEN; EZETIMIBE; FIBRIC ACID DERIVATIVE; GONADORELIN AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; MIPOMERSEN; NICOTINIC ACID; PROGESTERONE; RALOXIFENE; ROSUVASTATIN; SIMVASTATIN; TAMOXIFEN; THYROID HORMONE; TIBOLONE;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANTIANDROGEN THERAPY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APHERESIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION;

ANIMALS; ASCORBIC ACID; ASPIRIN; ESTROGENS; GUINEA PIGS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A);

EID: 79958229126     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428777     Document Type: Article

References (79)

1. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339(6222): 301-3.
2. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302(4): 412-23.
3. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301(22): 2331-39.
4. Kim BS, Jung HS, Bang OY, Chung CS, Lee KH, Kim GM. Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke. Atherosclerosis 2010; 212(2): 682-8.
5. Kim SJ, Song P, Park JH, et al. Biomarkers of asymptomatic carotid stenosis in patients undergoing coronary artery bypass grafting. Stroke 2011; 42(3): 734-9.
6. Klein JH, Hegele RA, Hackam DG, Koschinsky ML, Huff MW, Spence JD. Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol 2008; 28(10): 1851-6.
7. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The prime study. Atherosclerosis 2002; 163(2): 377-84.
8. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: Mechanistic insights from animal models. Clin Biochem 2004; 37(5): 333-43.
9. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90(1): 52-60.
10. Kraft HG, Lingenhel A, Pang RW, et al. Frequency distributions of apolipoprotein(a) kringle iv repeat alleles and their effects on lipoprotein(a) levels in caucasian, asian, and african populations: The distribution of null alleles is non-random. Eur J Hum Genet 1996; 4(2): 74-87.
11. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data. Arch Intern Med 2008; 168(6): 598-608.
12. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78(2-3): 145-50.
13. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): Insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004; 15(2): 167-74.
14. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in lp(a) catabolism but to differences in production rate. J Clin Invest 1994; 93(6): 2758-63.
15. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002; 48(9): 1454-9.
16. Ranga GS, Kalra OP, Tandon H, Gambhir JK, Mehrotra G. Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2007; 16(5): 220-4.
17. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-60.
18. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009; 203(2): 371-6.
19. Kagawa A, Azuma H, Akaike M, Kanagawa Y, Matsumoto T. Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999; 274(48): 34111-5.
20. Ushioda M, Makita K, Takamatsu K, Horiguchi F, Aoki D. Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older japanese women. Horm Metab Res 2006; 38(9): 581-6.
21. Bayrak A, Aldemir DA, Bayrak T, Corakci A, Dursun P. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein ai, apolipoprotein b and lipoprotein (a) in Turkish postmenopausal women. Arch Gynecol Obstet 2006; 274(5): 289-96.
22. Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein a1, apolipoprotein b and lipoprotein(a) in greek postmenopausal women. Gynecol Endocrinol 2004; 18(5): 244-57.
23. Hemelaar M, van der Mooren MJ, Mijatovic V, et al. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: A randomized, placebocontrolled study. Menopause 2003; 10(6): 550-8.
24. Perrone G, Capri O, Galoppi P, et al. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. Gynecol Obstet Invest 2009; 68(1): 33-9.
25. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337(9): 595-601.
26. Bukowska H, Stanosz S, Zochowska E, et al. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and c-reactive protein levels in postmenopausal women? Metabolism 2005; 54(1): 72-8.
27. Kiran H, Kiran G, Ekerbicer HC, Kilinc M. Effects of intranasal estradiol treatment on serum lipoprotein(a) and lipids in hysterectomized women. Gynecol Obstet Invest 2004; 57(4): 191-5.
28. Insull W, Jr., Davidson MH, Kulkarni PM, Siddhanti S, Ciaccia AV, Keech CA. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism 2005; 54(7): 939-46.
29. Denti L, Pasolini G, Cortellini P, et al. Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: Focus on lipoprotein(a). Clin Chem 1996; 42(8 Pt 1): 1176-81.
30. Hislop MS, St Clair Gibson A, Lambert MI, Noakes TD, Marais AD. Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. Atherosclerosis 2001; 159(2): 425-32.
31. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008; 52(2): 124-31.
32. Zysow BR, Kauser K, Lawn RM, Rubanyi GM. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler Thromb Vasc Biol 1997; 17(9): 1741-5.
33. Gaeta G, Lanero S, Barra S, et al. Sex hormones and lipoprotein(a) concentration. Expert Opin Investig Drugs 2011
34. Grover GJ, Mellstrom K, Malm J. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes. Curr Vasc Pharmacol 2007; 5(2): 141-54.
35. Pearce EN. Hypothyroidism and dyslipidemia: Modern concepts and approaches. Curr Cardiol Rep 2004; 6(6): 451-6.
36. Arem R, Escalante DA, Arem N, Morrisett JD, Patsch W. Effect of l-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). Metabolism 1995; 44(12): 1559-63.
37. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362(10): 906-16.
38. Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJ, Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA 1981; 78(4): 2591-5.
39. Ness GC, Pendleton LC, Li YC, Chiang JY. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, ldl receptor, hmg-coa reductase, farnesyl pyrophosphate synthetase and apolipoprotein a-i mrna levels in hypophysectomized rats. Biochem Biophys Res Commun 1990; 172(3): 1150-6.
40. Rath M, Pauling L. Hypothesis: Lipoprotein(a) is a surrogate for ascorbate. Proc Natl Acad Sci USA 1990; 87(16): 6204-7.
41. Rath M, Pauling L. Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion of the hypoascorbemic guinea pig. Proc Natl Acad Sci USA 1990; 87(23): 9388-90.
42. Jenner JL, Jacques PF, Seman LJ, Schaefer EJ. Ascorbic acid supplementation does not lower plasma lipoprotein(a) concentrations. Atherosclerosis 2000; 151(2): 541-4.
43. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003; 25(5): 1429-39.
44. Galvano F, Li Volti G, Malaguarnera M, Avitabile T, Antic T, Vacante M. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother 2009; 10(12): 1875-82.
45. Sirtori CR, Calabresi L, Ferrara S, et al. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper lp(a). Nutr Metab Cardiovasc Dis 2000; 10(5): 247-51.
46. Solfrizzi V, Capurso C, Colacicco AM, et al. Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. Atherosclerosis 2006; 188(2): 455-61.
47. Shakeri A, Tabibi H, Hedayati M. Effects of l-carnitine supplement on serum inflammatory cytokines, c-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with lp (a) hyperlipoproteinemia. Hemodial Int 2010; 14(4): 498-504.
48. Seccombe DW, James L, Hahn P, Jones E. L-carnitine treatment in the hyperlipidemic rabbit. Metabolism 1987; 36(12): 1192-6.
49. Gonbert S, Malinsky S, Sposito AC, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002; 164(2): 305-11.
50. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003; 89(8): 893-6.
51. Hernandez C, Francisco G, Ciudin A, Chacon P, Montoro B, Llaverias G, Blanco-Vaca F, Simo R. Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebocontrolled trial. Diabetes Metab 2010
52. Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu- Ciocca C. Effects of atorvastatin on lp(a) and lipoprotein profiles in hemodialysis patients. Ann Pharmacother 2008; 42(1): 9-15.
53. Horimoto M, Hasegawa A, Takenaka T, Fujiwara M, Inoue H, Igarashi K. Long-term administration of pravastatin reduces serum lipoprotein(a) levels. Int J Clin Pharmacol Ther 2003; 41(11): 524-30.
54. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling. Curr Med Res Opin 2001; 16(4): 269-75.
55. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: Effect of pravastatin. J Am Coll Cardiol 2006; 47(9): 1803-10.
56. Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79(1): 84-7.
57. Kinoshita M, Mikuni Y, Kudo M, et al. The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia. J Int Med Res 2002; 30(3): 271-81.
58. Tekin A, Tekin G, Guzelsoy D, et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am J Cardiol 2004; 94(2): 206-9.
59. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the scandinavian simvastatin survival study. Clin Genet 1997; 52(5): 254-61.
60. Gaw A, Murray HM, Brown EA. Plasma lipoprotein(a) [lp(a)] concentrations and cardiovascular events in the elderly: Evidence from the prospective study of pravastatin in the elderly at risk (prosper). Atherosclerosis 2005; 180(2): 381-8.
61. Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: Volume observations from the reversal (reversal of atherosclerosis with aggressive lipid lowering) study. J Am Coll Cardiol 2008; 52(1): 24-32.
62. Nair DR, Papadakis JA, Jagroop IA, Mikhailidis DP, Winder AF. Statins and fibrinogen. Lancet 1998; 351(9113): 1430; author reply 1431-2.
63. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein b-100 in patients with acute coronary syndromes in the miracl trial. Circulation 2004; 110(11): 1406-12.
64. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004; 5(6): 1385-98.
65. Goldberg AC. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. Am J Cardiol 2004; 94(1): 121-4.
66. Scanu AM, Bamba R. Niacin and lipoprotein(a): Facts, uncertainties, and clinical considerations. Am J Cardiol 2008; 101(8A): 44B-7.
67. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extendedrelease niacin or ezetimibe versus a statin alone (the compel study). Atherosclerosis 2007; 192(2): 432-7.
68. Sprecher DL. Raising high-density lipoprotein cholesterol with niacin and fibrates: A comparative review. Am J Cardiol 2000; 86(12A): 46L-50L.
69. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (niaspan): A long-term study. Am J Cardiol 1998; 82(12A): 74U-81U; discussion 85U-6U.
70. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210(2): 353-61.
71. Fonseca HA, Izar MC, Bianco HT, Fonseca FA. Ezetimibe, oxidized low density lipoprotein, lp (a), and dyslipidemia. J Atheroscler Thromb 2010; 17(8): 888.
72. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for ldl apheresis. Atherosclerosis 2010; 208(2): 317-21.
73. Parhofer KG, Geiss HC, Schwandt P. Efficacy of different lowdensity lipoprotein apheresis methods. Ther Apher 2000; 4(5): 382-5.
74. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6(3): 229-39.
75. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein b synthesis inhibitor, for lowering of ldl cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375(9719): 998-1006.
76. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein b synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010; 105(10): 1413-9.
77. Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010; 13(2): 103-11.
78. Hata T, Mera Y, Tadaki H, Kuroki Y, Kawai T, Ohta T, Kakutani M. Jtt-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in sprague-dawley rats. Diabetes Obes Metab 2011;.
79. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363(25): 2406-15.